Poliovirus

Poliovirus is the enterovirus that causes poliomyelitis, the paralytic disease that shaped twentieth-century public health and remains the target of the largest disease-eradication programme ever undertaken. It is a small, non-enveloped, positive-sense RNA virus of the family Picornaviridae, occurring as three serotypes that share a structure and a life cycle but do not cross-protect. Transmission is faecal-oral, and infection is silent in the great majority of those exposed. Its importance comes from a rare but devastating outcome: in roughly one in two hundred susceptible people the virus invades the spinal cord and destroys the motor neurons that drive voluntary movement, leaving permanent asymmetric flaccid paralysis. Two vaccines, the inactivated vaccine of Salk and the live oral vaccine of Sabin, turned a feared epidemic disease into one that is nearly gone: wild poliovirus type 1 now circulates in only two countries, and types 2 and 3 have been declared eradicated. Yet the live vaccine can itself, rarely, regain the capacity to paralyse and seed outbreaks, so the closing stages of eradication are dominated as much by vaccine-derived virus as by the wild agent. Poliovirus therefore sits at the centre of both a triumph of vaccinology and an unusually subtle endgame.

Discovery and historical significance

Poliomyelitis is an ancient disease, depicted in an Egyptian stele showing a withered leg, but it emerged as an epidemic problem only in the late nineteenth and early twentieth centuries, paradoxically as sanitation improved. In 1908 the Viennese investigators Karl Landsteiner and Erwin Popper transmitted the disease to monkeys, proving that poliomyelitis was caused by a filterable virus rather than a bacterium or toxin. The decades that followed were shaped by the large summer epidemics of the industrialised world, the iron-lung wards for patients paralysed in the muscles of respiration, and an intense search for a vaccine.

The decisive laboratory advance came in 1949, when John Enders, Thomas Weller and Frederick Robbins grew poliovirus in cultured non-neural human tissue, work recognised with the Nobel Prize in 1954. Growing the virus in culture made it possible to produce it in quantity and to measure neutralising antibody, the two prerequisites for a vaccine. Jonas Salk’s formalin-inactivated vaccine, given by injection, was licensed in 1955 amid enormous public attention; Albert Sabin’s live attenuated oral vaccine followed in the early 1960s. Between them these vaccines drove wild poliovirus from most of the world within four decades, and the virus became the second human pathogen, after smallpox, to be targeted for deliberate global eradication.

Classification, structure, and genome

Classification

Poliovirus belongs to the genus Enterovirus in the family Picornaviridae, small (“pico”) RNA viruses of the gut. Under the current International Committee on Taxonomy of Viruses (ICTV) binomial nomenclature the polioviruses are not a species in their own right: they are members of the single species Enterovirus coxsackiepol (the former Enterovirus C), which also contains several coxsackie A viruses and other numbered enteroviruses. Species assignment rests on genetic relatedness across the polyprotein and capsid rather than on disease.

Within that species poliovirus exists as three serotypes, types 1, 2 and 3, defined by neutralising antibody and clinically important because immunity to one does not protect against the others. A complete programme must therefore raise immunity to all three, and each type has had to be tackled separately in the eradication endgame. Type 1 has historically caused most paralytic disease and is the only wild type still circulating; types 2 and 3 have been declared eradicated in the wild.

Virion structure

The virion is a non-enveloped icosahedral particle about 30 nm across, lacking a lipid membrane and therefore resistant to organic solvents, bile and detergents, and stable at the acid pH of the stomach, properties that let it survive passage through the gut and persist for weeks in water and sewage. The capsid is built from sixty copies each of four proteins. VP1, VP2 and VP3 each fold into an eight-stranded antiparallel beta-barrel (the “jelly-roll”) and sit on the surface; the smaller VP4 lies on the inner face. Five protomers form a pentamer and twelve pentamers form the shell. Around each fivefold axis is a depression, the canyon, which is the receptor-binding site, and beneath its floor a hydrophobic pocket holds a lipid “pocket factor” that stabilises the particle. The principal neutralising antibody sites cluster on VP1, the most surface-exposed protein, which is why VP1 sequence also defines serotype.

Genome organisation

The genome is a single strand of positive-sense RNA of about 7.4 kb that acts directly as messenger RNA. A small viral protein, VPg (3B), is covalently linked to its 5’ end, and a poly(A) tail closes the 3’ end. A long 5’ untranslated region, roughly a tenth of the genome, contains two functional structures: a 5’ cloverleaf needed for RNA replication, and an internal ribosome entry site that allows the ribosome to start translation without a cap. The single open reading frame is translated into one polyprotein and then cut by viral proteases into the P1 region (the four capsid proteins VP1 to VP4), and the P2 and P3 regions (the non-structural proteins, including the 2A, 3C and 3CD proteases, the membrane-remodelling 2B and 2C, the VPg primer 3B, and the 3D RNA-dependent RNA polymerase). The 5’ untranslated region also carries the principal determinants of neurovirulence, the sequences that the attenuated vaccine strains have altered.

Replication cycle

Poliovirus completes its whole cycle in the cytoplasm, over a few hours, ending in cell death. It follows the canonical enteroviral arc.

Entry begins with attachment to its receptor, CD155 (the poliovirus receptor, an immunoglobulin-superfamily adhesion molecule), which inserts into the canyon. Receptor binding is not passive: it destabilises the particle, expelling VP4 and the hydrophobic amino terminus of VP1, which together form a pore in the cell membrane through which the RNA is delivered into the cytoplasm.

Once inside, the VPg peptide is removed and the genome is translated. Because enteroviruses cannot make a capped message, translation is driven by the internal ribosome entry site. The 2A protease then cleaves the host factor eIF4G, shutting down cap-dependent translation of host messenger RNA within about two hours while leaving the viral cap-independent route intact, which diverts the cell’s ribosomes to viral synthesis. The single polyprotein cleaves itself through its own proteases into the structural and non-structural proteins.

Genome replication takes place on clusters of cytoplasmic membrane vesicles induced by the viral 2B, 2C and 3A proteins. The 3D polymerase, primed by a uridylylated VPg, first copies the positive-strand genome into a negative strand, which then serves as template for many new positive strands, an asymmetric process that yields a large excess of genomes over templates. New capsids assemble around the RNA, and the immature particle matures when VP0 is cleaved to VP2 and VP4, locking the infectious virion. Progeny are released chiefly by cell lysis, though poliovirus can also exit non-lytically inside host membrane vesicles before the cell dies.

Pathogenesis

Poliovirus is swallowed and establishes its primary infection in the gut. Some replication occurs in the pharynx and tonsillar tissue, but most virus reaches the lower intestine, where it infects the lymphoid tissue of the gut wall, the M cells and follicle-associated epithelium overlying Peyer’s patches, which carry CD155 on their surface. From here a minor (primary) viraemia seeds other tissues; more extensive replication produces a larger secondary viraemia that coincides with symptomatic illness. In most people the infection goes no further than the gut and blood.

Only rarely does the virus reach the central nervous system, and it does so by more than one route. A haematogenous route across the blood-brain barrier is supported by the fact that viraemia is necessary for paralysis in primates. A neural route also operates: poliovirus can enter the terminals of motor nerves at the neuromuscular junction, which expresses CD155, and travel by fast retrograde axonal transport to the neuron cell body. This neural route explains two long-observed clinical phenomena, that paralysis often begins in a limb recently injected or exercised (“provocation poliomyelitis”), and that trauma to a limb predisposes it to paralysis.

In the cord the virus targets the large motor neurons of the anterior horn, the lower motor neurons that drive skeletal muscle, and destroys them, with an inflammatory infiltrate and neuronophagia; the brainstem motor nuclei and motor cortex can also be affected. Loss of these neurons produces the characteristic lower-motor-neuron pattern: flaccid, asymmetric weakness with lost reflexes and wasting, but no sensory loss, because the sensory pathways are spared. Why so few infections end this way is best explained by innate immunity: the type I interferon response confines the virus to the gut and blood in most hosts, and paralytic disease follows when replication in extraneural tissue is not held in check, allowing the virus to reach the cord. Neurovirulence itself is encoded largely in the 5’ untranslated region, the region the vaccine strains have attenuated.

Epidemiology

Humans are the only natural reservoir of poliovirus; there is no animal or environmental reservoir to sustain it, which is precisely what makes eradication biologically possible. Transmission is predominantly faecal-oral, especially where sanitation is poor, with some oral-oral spread; the virus is shed in stool for several weeks and can be recovered from sewage, which is the basis of environmental surveillance. Infection is a disease of childhood in endemic settings, and clusters in undervaccinated communities.

A striking historical feature is that improved sanitation raised, rather than lowered, the age and severity of paralytic disease. Where hygiene is poor, infants are infected very early while still partly protected by maternal antibody, and most infections are silent; as sanitation improves, first infection is delayed to older childhood and adulthood, when the paralytic-to-infection ratio is higher. This “hygiene paradox” produced the epidemic poliomyelitis of the early twentieth-century industrialised world.

The epidemiology is now dominated by the eradication endgame. Global cases have fallen by more than 99% since the World Health Assembly resolved on eradication in 1988. Wild poliovirus type 1 remains endemic only in Afghanistan and Pakistan; wild type 2 was declared eradicated in 2015 and wild type 3 in 2019, and the African region was certified free of wild poliovirus in 2020. Against this, vaccine-derived polioviruses, overwhelmingly type 2, now cause most of the world’s remaining paralytic polio, emerging in populations with low oral vaccine coverage. The detailed structure and surveillance of this endgame are the subject of the topic’s eradication material.

Natural history

The reported incubation period varies with the clinical form the infection takes. The mild abortive illness appears earliest, at about 3 to 5 days, and the aseptic meningitis of non-paralytic disease at around 3 to 6 days. Where the virus reaches the spinal cord, paralysis usually appears 7 to 21 days after infection, within an overall range of 3 to 35 days. Silent infection, the outcome in most people, incubates over roughly 7 to 14 days but never declares itself, though the virus is shed in the stool for weeks. The great majority of infections never progress beyond this silent gut replication and are cleared by antibody.

Where symptoms occur, the illness may be biphasic: a minor febrile “prodrome” settles, and in a fraction of patients a major illness of central nervous system involvement follows a few days later. Paralysis, when it develops, is preceded by severe muscle pain and loss of reflexes and evolves over one to two days, with progression continuing until the fever subsides. On average only about 1 in 200 infections in a susceptible population ends in paralysis. The short-term outcome is clear within days; the long-term outcome is largely determined in the first six months, during which most recovery of strength occurs. Muscles that show no recovery by then are usually permanently paralysed, with wasting and deformity. Overall mortality in spinal disease is around 5%, but was 50% or higher in bulbar disease before mechanical ventilation. Decades later, a proportion of survivors develop post-polio syndrome, new progressive weakness in previously affected muscles.

Clinical presentations and complications

Poliovirus infection produces a spectrum from silent infection to permanent paralysis. More than 90% of infections are entirely asymptomatic. Of the rest, most are one of two mild syndromes, and only a small minority are paralytic.

Abortive poliomyelitis, the “minor illness”, occurs in roughly 4% to 8% of infections: a brief non-specific febrile illness with sore throat, headache, malaise and gastrointestinal upset, resolving in a few days without neurological signs. Non-paralytic poliomyelitis is an aseptic meningitis, clinically indistinguishable from that caused by other enteroviruses, with fever, headache and neck stiffness but no weakness, and it too resolves.

Paralytic poliomyelitis is the feared outcome. It is an asymmetric flaccid paralysis that is characteristically proximal more than distal and affects legs more than arms, ranging from weakness of a single limb to quadriplegia. It is classified by the level involved: spinal polio (anterior-horn disease of the limbs and trunk); bulbar polio (about 10% to 15% of paralytic cases), involving the motor cranial nerves and the medullary centres, which threatens swallowing, speech and breathing; and bulbospinal disease combining the two. Respiratory failure, from diaphragmatic or bulbar involvement, is the main cause of death. Sensation is preserved throughout, a key point in distinguishing polio from other causes of paralysis.

Post-polio syndrome affects a substantial minority of survivors, characteristically 25 to 30 years after the acute illness: gradually progressive weakness, pain and wasting in previously affected muscle groups. The leading explanation is attrition of the enlarged motor units that compensated after the original neuron loss, rather than reactivation of the virus.

The clinical approach to acute flaccid paralysis

Because wild poliovirus is now rare, a child presenting with acute flaccid paralysis (AFP) far more often has another cause, and the clinician’s task is twofold: to recognise and support the patient, and to treat every case as possible polio until excluded. Any acute-onset floppy weakness in a child under 15 years is, for surveillance purposes, an AFP case and must be investigated as though it were polio. The clinical hallmarks that point towards poliomyelitis are asymmetric, proximal, purely motor flaccid weakness with preserved sensation, rapid onset (progressing over hours to a few days) and, often, fever at onset.

The principal differential diagnoses each carry distinguishing features:

Cause	Weakness pattern	Sensory signs	Key distinguishers
Poliomyelitis (and other enteroviruses)	Asymmetric, proximal, flaccid	None	Fever at onset; rapid progression; permanent asymmetric deficit
Guillain-Barre syndrome	Symmetric, ascending, flaccid	Often present (paraesthesiae)	Albuminocytological dissociation in cerebrospinal fluid; usually afebrile; can involve respiration symmetrically
Transverse myelitis	Symmetric, a sensory level	Present, with a level	Bladder involvement; clear sensory level; long-segment cord signal on imaging
Traumatic neuritis	One limb (injection site)	Variable in that limb	History of injection; confined to one limb
Acute flaccid myelitis (for example enterovirus D68)	Asymmetric, often upper limb	Usually none	Preceding respiratory illness; anterior-horn cord lesions on imaging

Two stool specimens for virus detection are collected from every AFP case, and a review at 60 days documents whether flaccid weakness persists, both to exclude poliovirus and to classify residual paralysis.

Diagnosis

The diagnosis of poliovirus infection is made in the laboratory by detecting the virus, and the specimen of choice is stool, because the virus is shed in large amounts in faeces for weeks. Two stool specimens collected on separate days are the standard, supported by throat swabs early in illness. The virus is only occasionally recovered from cerebrospinal fluid, so a negative spinal-fluid result does not exclude polio; cerebrospinal fluid in paralytic disease typically shows the changes of a viral meningitis.

Detection uses reverse transcription PCR and virus isolation in cell culture. Culture, though slower, remains central to the eradication programme, using sensitive cell lines including L20B cells engineered to express the poliovirus receptor, which favour poliovirus over other enteroviruses. The critical downstream step is intratypic differentiation, the molecular characterisation (by serotype-specific PCR and VP1 sequencing) that separates wild poliovirus, Sabin-like vaccine virus and vaccine-derived poliovirus, and assigns the serotype. This distinction, meaningless for routine enterovirus diagnosis where serotype rarely alters management, is decisive here, because it determines whether a case represents wild virus, a vaccine reaction or a circulating vaccine-derived strain. Serology has little role, given the difficulty of interpreting titres against a background of vaccination and prior exposure.

Management

There is no licensed specific antiviral for poliovirus, and treatment of paralytic disease is entirely supportive. In the acute phase this means careful observation for respiratory and bulbar failure, with mechanical ventilation where the muscles of respiration or the brainstem centres are involved, the modern successor to the iron lung, together with pain relief, attention to bladder and bowel, and prevention of the complications of immobility. Once the acute phase passes, rehabilitation to preserve function and prevent contractures is the mainstay, and later orthopaedic care may address residual deformity. Post-polio syndrome is managed with energy conservation, physiotherapy and orthotic support.

Antiviral development has focused on the capsid-binding inhibitors, which lodge in the hydrophobic pocket beneath the canyon and block uncoating. Pocapavir has potent anti-poliovirus activity and has been used experimentally, notably to try to clear virus from immunodeficient individuals who excrete poliovirus for prolonged periods, a specific eradication problem, though resistance emerges readily and no such agent is in routine use.

Prevention and public health

Vaccination

Two vaccines control poliovirus, and understanding their differences is central to both clinical practice and the eradication endgame.

Inactivated poliovirus vaccine (IPV), developed by Salk, is a formalin-inactivated preparation of all three serotypes given by injection. It raises serum neutralising antibody (IgG) that protects the individual against paralytic disease, but induces little intestinal mucosal immunity, so a vaccinated person can still be infected in the gut and shed virus. It cannot cause poliomyelitis and is safe in immunocompromised people. Its early history includes the Cutter incident of 1955, in which incompletely inactivated vaccine caused paralytic cases, a founding lesson in vaccine manufacturing safety.

Oral poliovirus vaccine (OPV), developed by Sabin, is a live attenuated vaccine given by mouth. Because it replicates in the gut it induces both serum antibody and strong intestinal mucosal immunity (secretory IgA), which interrupts faecal-oral transmission, and vaccine virus spread to close contacts extends immunity through a community. It is cheap, needs no needle or trained vaccinator, and was for these reasons the mainstay of global eradication. OPV comes in several formulations: trivalent (tOPV, types 1, 2 and 3), bivalent (bOPV, types 1 and 3) and monovalent (mOPV) preparations used for specific serotypes in outbreaks.

The trade-off between the two vaccines is the crux of policy:

Feature	OPV (live, oral)	IPV (inactivated, injected)
Mucosal (gut) immunity	Strong; blocks transmission	Weak
Systemic (humoral) immunity	Good	Good
Protects the individual	Yes	Yes
Interrupts community spread	Yes	Limited
Administration	Oral, no needle, low cost	Injection, trained staff
Contact (herd) immunisation	Yes, via shed virus	No
Can cause paralysis	Yes, rarely (see below)	No
Use in immunocompromised	Contraindicated	Safe

OPV’s live nature carries two rare but defining risks. Vaccine-associated paralytic poliomyelitis (VAPP) is paralysis caused directly by the vaccine virus in a recipient or contact, occurring in roughly one per several hundred thousand to one per few million doses. More important for eradication, the attenuated virus can, on prolonged replication, revert towards neurovirulence and transmissibility: the Sabin type 3 strain, for example, is attenuated by only a small number of changes, and a single reversion in its 5’ untranslated region begins to restore virulence. Reverting virus that spreads in an undervaccinated population becomes a vaccine-derived poliovirus (VDPV), which can paralyse and circulate exactly like wild virus. VDPVs are classified as circulating (cVDPV, with evidence of person-to-person spread), immunodeficiency-associated (iVDPV, from a chronically infected immunodeficient excreter) or ambiguous (aVDPV, of unclear source), and type 2 accounts for the large majority.

This risk drove a change of strategy. After wild type 2 was eradicated, the world withdrew the type 2 component of OPV in the 2016 “switch” from trivalent to bivalent OPV, and IPV was introduced into routine schedules to maintain type 2 immunity without live type 2 virus. A genetically stabilised novel oral vaccine against type 2 (nOPV2), engineered to revert far less readily, is now used to respond to type 2 outbreaks. The general direction of travel is away from live OPV and towards IPV as wild virus disappears.

Surveillance and notification

Poliomyelitis is a notifiable disease everywhere, and the detection of any poliovirus is a public health emergency. The system that finds it is surveillance for acute flaccid paralysis, the investigation with stool virology of every child presenting with sudden floppy paralysis. This is increasingly backed by environmental surveillance, the testing of sewage for poliovirus, which can reveal silent circulation before any paralytic case appears and is often far more sensitive than clinical surveillance where paralysis has become rare. Together with the containment of poliovirus in laboratories and vaccine-production sites, this case-finding is the backbone of the global effort to interrupt poliovirus transmission.

South African context

South Africa has been free of indigenous wild poliovirus for decades and lies within the WHO African Region, which was certified free of wild poliovirus in 2020. The residual risk is importation, either of wild virus from the two remaining endemic countries or, more pertinently for the continent, of circulating vaccine-derived poliovirus from outbreaks elsewhere in Africa, which keeps high vaccination coverage and sensitive surveillance essential.

Polio vaccination is delivered through the Expanded Programme on Immunisation (EPI-SA). In line with the global endgame, South Africa switched from trivalent to bivalent OPV in 2016 and uses both vaccine types: bivalent OPV is given at birth, and inactivated poliovirus vaccine within the combination (hexavalent) vaccine at 6, 10 and 14 weeks, with a booster at 18 months. This schedule combines OPV’s mucosal, transmission-blocking immunity with the safety and type 2 cover of IPV.

Case-finding rests on acute flaccid paralysis surveillance coordinated by the National Institute for Communicable Diseases (NICD), to which stool specimens from every case of childhood acute flaccid paralysis are referred for poliovirus testing, with specimen, timing and cold-chain standards that follow the global requirements.

South Africa supplements this clinical surveillance with environmental (wastewater) surveillance, sampling sewage for poliovirus so that silent circulation can be caught before any child is paralysed. Piloted from 2018 at four sites in Tshwane and Johannesburg and added to the national system from 2019, it has grown to more than 26 sampling sites across the major metropolitan areas and districts at higher risk of importation, with all samples processed at the NICD. Because the great majority of poliovirus infections cause no symptoms, this sewage-based system is a more sensitive early warning of an imported wild or vaccine-derived virus than paralysis-based surveillance alone, an important safeguard for a country whose polio-free status is threatened chiefly by importation.

References and recommended reading

Romero JR. Enteroviruses. In: Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. 4th ed. Washington (DC): ASM Press; 2016. The foundational account of enterovirus virology, poliovirus pathogenesis and the clinical syndromes drawn on throughout this profile.

Coyne CB, Oberste MS, Pallansch MA. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Howley PM, Knipe DM, editors. Fields Virology. 7th ed. Philadelphia: Wolters Kluwer; 2023. The current molecular and epidemiological reference, including the vaccine-derived poliovirus determinants and the neuroattenuating mutations.

World Health Organization. Global guidance for conducting acute flaccid paralysis (AFP) surveillance in the context of poliovirus eradication. 2nd ed. Geneva: World Health Organization; 2026. The authoritative source for the acute flaccid paralysis case definition and surveillance standards referred to here.

National Department of Health, South Africa. Expanded Programme on Immunisation (EPI-SA): routine childhood immunisation schedule and programme overview. 2024 revision. The authoritative source for the South African polio vaccination schedule cited in the South African context.

Manyanga D, Maseti E, Mokoena K, Buthelezi T, Mthetwa S, Mokoena S, Khosa-Lesola E, Wanyoike S. Assessment of environmental surveillance for the detection of poliovirus implementation in the metropolitan districts of South Africa, 2020-2023. Pan African Medical Journal. 2025;51(58). The source for the South African environmental (wastewater) surveillance programme.